Lille (France), Cambridge (Massachusetts, United States), February 29th, 2012 – GENFIT (Alternext: ALGFT;
ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development,
focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today
announces its participation at the 5th Annual European Life Sciences CEO Forum, in Zurich on March 6th-7th,
During this conference, dedicated to partnering and investing in the Life Science and Biotech industries, Jean-
François Mouney, CEO of GENFIT, will outline the Company’s perspectives to the pharmaceutical and
specialized financial communities, and will notably present the latest results of toxicology studies and clinical
trials obtained for GFT505 in NASH.
GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in
therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia,
inflammatory diseases…). GENFIT uses a multi-pronged approach based on early diagnosis, preventive
solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in
partnership with leading pharmaceutical companies (SANOFI, SERVIER, …), to address these major public health
concerns and their unmet medical needs.
GENFIT’s research programs have resulted in the creation of a rich and diversified pipeline of drug candidates
at different stages of development, including GENFIT’s lead proprietary compound, GFT505, that is currently in
With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees.
GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN:
Jean-François Mouney – CEO & Chairman of the Management Board
Ph. +333 2016 4000
MILESTONES – Press Relations
Ph. +33 1 7544 8740 / +336 8788 4726 – email@example.com